Track market-moving stories before they get noisy

Beacon Pointe Advisors LLC acquired a new stake in Carpenter Technology Corporation (NYSE:CRS – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 1,502 shares of the basic materials company’s stock, valued at approximately $926,000.

A number of other hedge funds have also modified their holdings of CRS. Keating Financial Advisory Services Inc. acquired a new position in shares of Carpenter Technology in the second quarter valued at approximately $29,000. Whittier Trust Co. of Nevada Inc. acquired a new stake in shares of Carpenter Technology during the first quarter worth $30,000. SJS Investment Consulting Inc. grew its position in Carpenter Technology by 81.8% in the 1st quarter. SJS Investment Consulting Inc. now owns 80 shares of the basic materials company’s stock valued at $32,000 after buying an additional 36 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in Carpenter Technology in the 2nd quarter valued at $55,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Carpenter Technology in the 2nd quarter valued at $56,000. 92.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth A number of equities analysts have recently issued reports on the company. TD Cowen increased their target price on Carpenter Technology from $470.00 to $650.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. Weiss Ratings downgraded Carpenter Technology from a “buy (b+)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Zacks Research raised Carpenter Technology from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 15th. Wells Fargo & Company increased their price objective on Carpenter Technology from $425.00 to $540.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Carpenter Technology from $705.00 to $700.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Carpenter Technology has an average rating of “Buy” and a consensus price target of $577.25.

Read Our Latest Analysis on CRS Carpenter Technology Stock Up 0.1% CRS stock opened at $476.72 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.81 and a quick ratio of 2.23. The company’s 50 day simple moving average is $555.47 and its 200-day simple moving average is $475.21. The firm has a market capitalization of $23.63 billion, a PE ratio of 45.32, a P/E/G ratio of 1.71 and a beta of 1.25. Carpenter Technology Corporation has a 12 month low of $228.00 and a 12 month high of $625.98.

Carpenter Technology (NYSE:CRS – Get Free Report) last announced its earnings results on Thursday, July 30th. The basic materials company reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.09 by $0.14. The firm had revenue of $679.70 million during the quarter, compared to the consensus estimate of $863.33 million. Carpenter Technology had a net margin of 16.96% and a return on equity of 26.46%. The firm’s revenue for the quarter was up 12.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.21 EPS. Equities analysts expect that Carpenter Technology Corporation will post 13.09 earnings per share for the current fiscal year.

Carpenter Technology Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Investors of record on Tuesday, August 25th will be given a dividend of $0.20 per share. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $0.80 annualized dividend and a yield of 0.2%. Carpenter Technology’s dividend payout ratio is 7.60%.

Insiders Place Their Bets In other Carpenter Technology news, CEO Tony R. Thene sold 57,456 shares of the company’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $483.90, for a total transaction of $27,802,958.40. Following the completion of the sale, the chief executive officer directly owned 439,631 shares in the company, valued at $212,737,440.90. This represents a 11.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ramin Younessi sold 438 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $493.15, for a total value of $215,999.70. Following the sale, the director owned 1,953 shares of the company’s stock, valued at $963,121.95. This represents a 18.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 109,721 shares of company stock valued at $53,091,824. Insiders own 2.90% of the company’s stock.

Carpenter Technology Profile (Free Report)

Carpenter Technology Corporation engages in the manufacture, fabrication, and distribution of specialty metals in the United States, Europe, the Asia Pacific, Mexico, Canada, and internationally. It operates in two segments, Specialty Alloys Operations and Performance Engineered Products. The company offers specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels, as well as additives, and metal powders and parts. It serves to aerospace, defense, medical, transportation, energy, industrial, and consumer markets.

See Also Five stocks we like better than Carpenter Technology Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season Insiders Are Betting Big on These 3 Healthcare Stocks 3 Stocks for Investors Who Still Believe Cash Is King Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason Want to see what other hedge funds are holding CRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Carpenter Technology Corporation (NYSE:CRS – Free Report).

Receive News & Ratings for Carpenter Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carpenter Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways Carpenter Technology's $400M Athens project is on schedule and within budget for FY28.The expansion will add 9,000 tons of high-purity melt capacity, a 7% rise from FY19 shipments.CRS targets $1.2-$1.3B in FY29 operating income, up from $702M in FY26. Carpenter Technology’s (CRS - Free Report) brownfield expansion finished fiscal 2026 on schedule and within budget. The project is slated for completion by the start of fiscal 2028, accelerating CRS’s earnings growth profile.

The company is investing in a $400-million brownfield expansion project based in Athens. The project is aimed at adding high-purity primary and secondary melt capacity to the company’s existing downstream finishing assets, which will boost long-term growth.

The company is aiming to expand its capacity with a vacuum induction melting furnace, a crucial piece of equipment to manufacture high-purity specialty alloys. The brownfield capacity expansion project is designed to add 9,000 additional tons, marking a 7% rise from Carpenter Technology’s 2019 shipments.

The construction phase of the project is well underway with major equipment being delivered and installed. The company is focused on completing construction and preparing for a smooth startup of operations.

Carpenter Technology expects cash generation to further increase beyond fiscal 2027, driven by earnings expansion and profitability contributions from the brownfield project. CRS set a fiscal 2029 operating income target of $1.2-$1.3 billion, suggesting a solid jump from the $702 million reported in fiscal 2026. The upside will be fueled by both a robust underlying demand environment and the added capacity from the brownfield expansion. The company projects growth beyond fiscal 2026 as the brownfield project will still ramp up production amid a growing underlying demand environment.

Growth Strategies by Other Steel StocksCommercial Metals Company’s (CMC - Free Report) Transform, Advance, Grow Program focuses on driving higher through-the-cycle margins, earnings, cash flows and ROIC. Commercial Metals expects an annualized EBITDA benefit of $150 million in fiscal 2026 from the program.

Launched in 2024, the TAG program aims to drive consistency across all areas of the business for Commercial Metals. The program is designed to optimize logistics, reduce input consumption, lower costs and boost energy efficiency.

Cleveland-Cliffs Inc. (CLF - Free Report) is investing $1 billion to modernize its Middletown Works facility in Ohio, supported by a $500-million award from the U.S. Department of Energy (“DOE”). Cleveland-Cliffs and the DOE will each fund $500 million of the project. The investment is expected to be deployed over the next four years while maintaining uninterrupted steel production at the facility. The project represents a rescoping of Cleveland-Cliffs’ previously planned decarbonization initiative at Middletown Works.

CRS’s Price Performance, Valuations & EstimatesCarpenter Technology’s shares have surged 97.5% over the past year compared with the industry’s growth of 83.8%. In comparison, the Zacks Basic Materials sector and the S&P 500 have returned 37.1% and 22.4%, respectively.

Image Source: Zacks Investment Research

CRS is currently trading at a forward price/sales ratio of 6.87 compared with the industry's 2.69.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for fiscal 2027 sales is pegged at $3.04 billion, indicating an 8.8% year-over-year jump. The consensus mark for the year’s earnings is pegged at $13.08 per share, indicating a year-over-year rise of 21%.

The Zacks Consensus Estimate for fiscal 2028 sales implies 8.4% year-over-year growth, and the same for earnings suggests a rise of 19.4%.

EPS estimates for fiscal 2027 and 2028 have moved north over the past 60 days.

Image Source: Zacks Investment Research

CRS currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

SummaryThe article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield.We use our proprietary models to rate both quantitatively and qualitatively and select the top 10 names from an initial list of nearly 500 dividend stocks.The final list of ten stocks is chosen based on sector diversity, high-growth quality scores, and positive momentum and is suitable for investors in the accumulation phase.This series and portfolio have completed 3-plus years, and the HG Portfolio has returned 28% on an annualized basis versus 19% for the S&P 500. On a cumulative basis, the performance is 143% versus 86%, respectively.Looking for a portfolio of ideas like this one? Members of High Income DIY Portfolios get exclusive access to our subscriber-only portfolios. Learn More » Olivier Le Moal/iStock via Getty Images

Note: The stocks shortlisted and highlighted in this article are not buy recommendations per se but rather candidates for further research. Before making any investments, please use due diligence, considering your personal goals and risk tolerance. Also, some sections

59.99K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABT, ABBV, CI, JNJ, PFE, NVS, NVO, AZN, UNH, CL, CLX, UL, NSRGY, PG, TSN, ADM, BTI, MO, PM, KO, PEP, EXC, D, DEA, DEO, ENB, MCD, BAC, PRU, UPS, WMT, WBA, CVS, LOW, AAPL, IBM, CSCO, MSFT, INTC, T, VZ, CVX, XOM, VLO, ABB, ITW, MMM, LMT, LYB, RIO, O, NNN, WPC, ARCC, ARDC, AWF, BME, BST, CHI, TLT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer: The information presented in this article is for informational purposes only and in no way should be construed as financial advice or a recommendation to buy or sell any stock. The author is not a financial advisor. Please always do further research and do your own due diligence before making any investments. Every effort has been made to present the data/information accurately; however, the author does not claim 100% accuracy. The stock portfolios presented here are model portfolios for demonstration purposes. For the complete list of our LONG positions, please see our profile on Seeking Alpha.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

On CNBC’s “Mad Money Lightning Round,” Jim Cramer recommended buying Carpenter Technology (NYSE:CRS).

As per recent news, Carpenter Technology announced on Wednesday a $1 billion buyback program and declared a quarterly cash dividend of 20 cents per share.

DXC Technology Company (NYSE:DXC) is a “value trap,” Cramer said.

DXC Technology, on July 30, reported mixed results for the second quarter. The company’s quarterly earnings were 40 cents per share, which missed the analyst consensus estimate of 41 cents per share. The company reported quarterly sales of $2.999 billion, which beat the analyst consensus estimate of $2.985 billion.

“If you want to speculate, then I bless it,” Cramer said when asked about Senseonics Holdings, Inc. (NASDAQ:SENS).

On the earnings front, Senseonics Holdings, on Aug. 6, posted upbeat second-quarter sales and raised its FY2026 forecast.

Cramer said he doesn’t know what’s driving Ubiquiti Inc. (NYSE:UI) right now.

Ubiquiti reported worse-than-expected third-quarter financial results on May 8.

Hess Midstream LP (NYSE:HESM) is a “winner,” Cramer said.

Lending support to his choice, Hess Midstream, on Aug. 3, posted better-than-expected quarterly results.

As per recent news, Zeta Global announced on Aug. 6 that Leah Pope will join the company as chief marketing officer.

UL Solutions, on Aug. 4, posted better-than-expected earnings and sales results for the second quarter.

Coupang, on Aug. 4, reported second-quarter financial results that were worse than expected.

Price Action:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

PHILADELPHIA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) announced today that Ken Giacobbe has been appointed to the Company's Board of Directors, effective August 11, 2026.

Posted by Defense World Staff on Aug 7th, 2026

Canandaigua National Bank & Trust Co. bought a new stake in Carpenter Technology Corporation (NYSE:CRS – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 960 shares of the basic materials company’s stock, valued at approximately $592,000.

A number of other institutional investors have also recently made changes to their positions in CRS. Geneos Wealth Management Inc. purchased a new position in Carpenter Technology in the 2nd quarter valued at approximately $28,000. Whittier Trust Co. of Nevada Inc. bought a new stake in Carpenter Technology during the 1st quarter valued at $30,000. SJS Investment Consulting Inc. lifted its position in shares of Carpenter Technology by 81.8% during the first quarter. SJS Investment Consulting Inc. now owns 80 shares of the basic materials company’s stock worth $32,000 after acquiring an additional 36 shares in the last quarter. Headlands Technologies LLC purchased a new stake in shares of Carpenter Technology during the second quarter worth $43,000. Finally, Rakuten Securities Inc. bought a new position in shares of Carpenter Technology in the second quarter worth $45,000. Hedge funds and other institutional investors own 92.03% of the company’s stock.

Carpenter Technology Trading Down 2.4% Carpenter Technology stock opened at $556.93 on Friday. The stock has a market cap of $27.67 billion, a P/E ratio of 52.94, a PEG ratio of 2.07 and a beta of 1.25. Carpenter Technology Corporation has a fifty-two week low of $228.00 and a fifty-two week high of $625.98. The firm’s fifty day moving average price is $561.58 and its 200-day moving average price is $454.22. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.23 and a current ratio of 3.81.

Carpenter Technology (NYSE:CRS – Get Free Report) last announced its earnings results on Thursday, July 30th. The basic materials company reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.09 by $0.14. Carpenter Technology had a return on equity of 26.46% and a net margin of 16.96%.The business had revenue of $679.70 million for the quarter, compared to analyst estimates of $863.33 million. During the same period in the prior year, the company earned $2.21 EPS. The company’s quarterly revenue was up 12.6% compared to the same quarter last year. Equities research analysts forecast that Carpenter Technology Corporation will post 12.92 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades Several brokerages have recently weighed in on CRS. TD Cowen lifted their price target on Carpenter Technology from $470.00 to $650.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Susquehanna dropped their price objective on Carpenter Technology from $680.00 to $600.00 and set a “positive” rating on the stock in a report on Friday, July 31st. BTIG Research raised their target price on Carpenter Technology from $450.00 to $620.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Wells Fargo & Company lifted their target price on Carpenter Technology from $425.00 to $540.00 and gave the company an “equal weight” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. lowered their price target on shares of Carpenter Technology from $705.00 to $700.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Carpenter Technology has a consensus rating of “Buy” and an average price target of $577.25.

Get Our Latest Stock Report on CRS

Carpenter Technology Company Profile (Free Report)

Carpenter Technology Corporation engages in the manufacture, fabrication, and distribution of specialty metals in the United States, Europe, the Asia Pacific, Mexico, Canada, and internationally. It operates in two segments, Specialty Alloys Operations and Performance Engineered Products. The company offers specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels, as well as additives, and metal powders and parts. It serves to aerospace, defense, medical, transportation, energy, industrial, and consumer markets.

Featured Stories Five stocks we like better than Carpenter Technology Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling 4 Oil and Gas ETF Plays as Prices Stay Sky-High What Tesla Stands to Lose If It Walks Away From China Disney Sets Up for a Magical Year in 2027 Want to see what other hedge funds are holding CRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Carpenter Technology Corporation (NYSE:CRS – Free Report).

Receive News & Ratings for Carpenter Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carpenter Technology and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECanandaigua National Bank & Trust Co. Takes $621,000 Position in Ross Stores, Inc. $ROST

Key Takeaways CRS posted record Q4 operating income of $206.9M, driven by strong demand and execution.CRS expects fiscal 2027 operating income of $850M-$880M, up 21%-25% from fiscal 2026.CRS' brownfield expansion remains on schedule, supporting future aerospace capacity growth. Carpenter Technology Corporation (CRS - Free Report) entered fiscal 2027 with record profitability and an expanded earnings outlook, as management highlighted accelerating aerospace demand, improving margins and long-term capacity expansion. The company also introduced a fiscal 2029 operating income target that reflects continued confidence in its growth trajectory.

Management emphasized that productivity gains, favorable pricing, product mix improvements and demand across high-value markets are supporting results. The call also focused on the brownfield expansion project and how it could extend earnings growth beyond the current year.

CRS Extends Record Profitability RunCarpenter Technology reported fourth-quarter fiscal 2026 earnings per share of $3.23, exceeding the Zacks Consensus Estimate of $3.03. Revenues came in at $851 million, ahead of the Zacks Consensus Estimate of $847.8 million.

The company delivered record quarterly operating income of $206.9 million, up 37% year over year and 11% sequentially. Chief executive officer Tony Thene said the performance reflected continued operational execution and strengthening demand across specialized end markets.

Carpenter Technology completed fiscal 2026 with adjusted operating income of $702 million, up 34% from fiscal 2025, making it the company’s most profitable year on record.

Carpenter Technology Expands Margin GainsThe Specialty Alloys Operations ("SAO") segment remained the primary earnings driver, generating $229.7 million of operating income in the quarter. The segment’s adjusted operating margin excluding surcharge revenues reached a record 37.8% compared with 35.6% in the prior quarter and 30.5% a year earlier.

Thene said margin expansion was supported by productivity improvements, pricing realization and better product mix. Chief financial officer Timothy Lain noted that changes in average selling price per pound reflected shipment mix rather than pricing pressure, as lower-priced products maintained attractive margins.

SAO sales excluding surcharge increased 11% year over year on 23% higher volume. Management said ongoing production scheduling discipline and efficiency improvements continue to support profitability.

CRS Sees Aerospace Demand AcceleratingAerospace and defense remained a major growth driver, with fourth-quarter sales increasing 17% year over year. Thene said aerospace activity is improving as aircraft manufacturers increase production rates and customers seek additional material availability.

Management highlighted strong demand from engine manufacturers, fastener customers and structural suppliers. Thene said some structural customers remain cautious but are ordering below expected demand levels, creating additional upside if ordering patterns normalize.

A TD Cowen analyst asked about the drivers behind fiscal 2027 growth. Thene said aircraft build rates, particularly from Boeing and Airbus, are expected to be the most significant factor, alongside pricing, volume growth and continued productivity actions.

Carpenter Technology Builds Capacity for GrowthCarpenter Technology’s brownfield capacity expansion project remained on schedule and budget, with completion expected by the start of fiscal 2028. Management said the project is expected to become an incremental contributor to operating income in fiscal 2028.

A Deutsche Bank analyst asked about the project’s contribution to the fiscal 2029 outlook. Lain said the company expects the expansion to contribute meaningfully during the ramp-up period, with the previously stated $150 million operating income contribution target for 2030 remaining in place.

Management noted that the project is designed to support future demand rather than simply meet current requirements. The company expects capacity additions to strengthen its ability to serve aerospace and other high-value applications.

CRS Raises Fiscal 2027 ExpectationsCarpenter Technology expects fiscal 2027 operating income of $850 million to $880 million, representing 21% to 25% growth from fiscal 2026. The company also expects adjusted free cash flow of $400 million to $430 million during the year.

For the first quarter of fiscal 2027, management expects operating income of $195 million to $200 million, including SAO operating income of $218 million to $222 million.

Looking further ahead, Carpenter Technology established a fiscal 2029 operating income target of $1.2 billion to $1.3 billion. Management said the target reflects demand strength, productivity improvements and contributions from the brownfield expansion.

Carpenter Technology Maintains Capital DisciplineThe company generated $605 million in operating cash flow during fiscal 2026 and $362.3 million in adjusted free cash flow. Management said strong cash generation supports both growth investments and shareholder returns.

Carpenter Technology repurchased $179.1 million of shares during fiscal 2026 and continued paying its quarterly dividend. The company ended the quarter with total liquidity of $892.4 million, including cash and available borrowings.

Management reiterated a balanced capital allocation approach focused on investing in expansion projects while returning capital through dividends and share repurchases.

Zacks Signals for CRSCarpenter Technology carries a Zacks Rank #1 (Strong Buy). The Zacks Rank is driven by earnings estimate revisions and is designed to help identify stocks with potential relative outperformance over the next one to three months. The Rank can change as analysts revise estimates following quarterly results. 

You can see the complete list of today’s Zacks #1 Rank stocks here.

The stock has a Value Score of F, Growth Score of A, Momentum Score of C and VGM Score of C. Zacks Style Scores range from A to F, with higher scores representing stronger characteristics for each investment style category.

Carpenter Technology Corporation (CRS) Q4 2026 Earnings Call July 30, 2026 10:00 AM EDT

Company Participants

John Huyette - VP of Corporate Development & Investor Relations
Tony Thene - President, CEO & Chairman of the Board
Timothy Lain - Senior VP & CFO

Conference Call Participants

Scott Deuschle - Deutsche Bank AG, Research Division
Gautam Khanna - TD Cowen, Research Division
David Strauss - Wells Fargo Securities, LLC, Research Division
Bennett Moore - JPMorgan Chase & Co, Research Division
Joshua Sullivan - JonesTrading Institutional Services, LLC, Research Division
Andre Madrid - BTIG, LLC, Research Division

Presentation

Operator

Hello, everyone, and thank you for joining us, and welcome to the Carpenter Technology Corp Q4 FY '26 Earnings Presentation. [Operator Instructions] I will now hand the conference over to John Huyette, Vice President, Investor Relations. Please go ahead.

John Huyette
VP of Corporate Development & Investor Relations

Thank you, operator. Good morning, everyone, and welcome to the Carpenter Technology Earnings Conference Call for the fiscal 2026 Fourth Quarter ended June 30, 2026. This call is also being broadcast over the Internet along with presentation slides. For those of you listening by phone, you may experience a time delay in slide movement. Speakers on the call today are Tony Thene, Chairman, President and Chief Executive Officer; and Tim Lain, Senior Vice President and Chief Financial Officer. Statements made by management during this earnings presentation that are forward-looking statements are based on current expectations.

Risk factors that could cause actual results to differ materially from these forward-looking statements can be found in Carpenter Technology's most recent SEC filings, including the company's report on Form 10-K for the year ended June 30, 2025, Forms 10-Q for the quarters ended September 30, 2025, December 31, 2025, and March 31, 2026, and the exhibits attached to those filings.

Please also note that

Carpenter Technology (CRS - Free Report) came out with quarterly earnings of $3.23 per share, beating the Zacks Consensus Estimate of $3.03 per share. This compares to earnings of $2.21 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +6.60%. A quarter ago, it was expected that this maker of stainless steels and special alloys would post earnings of $2.59 per share when it actually produced earnings of $2.77, delivering a surprise of +6.95%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Carpenter, which belongs to the Zacks Steel - Speciality industry, posted revenues of $851 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.38%. This compares to year-ago revenues of $755.6 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Carpenter shares have added about 68.5% since the beginning of the year versus the S&P 500's gain of 6.9%.

What's Next for Carpenter?While Carpenter has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Carpenter was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #1 (Strong Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.93 on $809.77 million in revenues for the coming quarter and $12.81 on $3.38 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Steel - Speciality is currently in the top 2% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Metallus (MTUS - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 3.

This maker of steel large bars and seamless mechanical tubing is expected to post quarterly earnings of $0.26 per share in its upcoming report, which represents a year-over-year change of +30%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Metallus' revenues are expected to be $331.05 million, up 8.7% from the year-ago quarter.

The upcoming report from Carpenter Technology (CRS - Free Report) is expected to reveal quarterly earnings of $3.03 per share, indicating an increase of 37.1% compared to the year-ago period. Analysts forecast revenues of $847.78 million, representing an increase of 12.2% year over year.

Over the last 30 days, there has been an upward revision of 3.6% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.

Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.

While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.

Bearing this in mind, let's now explore the average estimates of specific Carpenter metrics that are commonly monitored and projected by Wall Street analysts.

Analysts' assessment points toward 'Net Sales- End-Use Market Excluding Surcharge Revenue- Total' reaching $687.41 million. The estimate indicates a year-over-year change of +10.2%.

The consensus estimate for 'Net Sales- End-Use Market Excluding Surcharge Revenue- Surcharge revenue' stands at $151.87 million. The estimate indicates a year-over-year change of +15.1%.

The consensus among analysts is that 'Net Sales- Performance Engineered Products' will reach $102.58 million. The estimate indicates a year-over-year change of -1.9%.

It is projected by analysts that the 'Net Sales- Specialty Alloys Operations' will reach $762.11 million. The estimate suggests a change of +13.1% year over year.

Based on the collective assessment of analysts, 'Volumes Sold in Pounds - Specialty Alloys Operations' should arrive at 51.46 million. Compared to the present estimate, the company reported 46.87 million in the same quarter last year.

Analysts expect 'Volumes Sold in Pounds' to come in at 53.29 million. The estimate compares to the year-ago value of 48.75 million.

The average prediction of analysts places 'Operating Income- Performance Engineered Products' at $6.80 million. The estimate is in contrast to the year-ago figure of $11.70 million.

Analysts forecast 'Operating Income- Specialty Alloys Operations' to reach $227.64 million. The estimate is in contrast to the year-ago figure of $167.00 million.

View all Key Company Metrics for Carpenter here>>>

Shares of Carpenter have demonstrated returns of -9.2% over the past month compared to the Zacks S&P 500 composite's +1.9% change. With a Zacks Rank #1 (Strong Buy), CRS is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

PHILADELPHIA, July 27, 2026 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE: CRS) announced today that Brian Malloy, the Company's President and Chief Executive Officer, passed away suddenly and unexpectedly on Friday, July 24. The Carpenter Technology team extends its sincere condolences to his family, friends, and colleagues.

Whether you're a growth, value, income, or momentum-focused investor, building a successful investment portfolio takes skill, research, and a little bit of luck.

But what's the best way to find the right combination of stocks? Because funding things like your retirement, your kids' college tuition, or your short- and long-term savings goals will definitely require significant returns.

Enter the Zacks Rank.

What is the Zacks Rank?A unique, proprietary stock-rating model, the Zacks Rank uses earnings estimate revisions, or changes to a company's earnings expectations, to help investors create a winning portfolio.

There are four main factors behind the Zacks Rank: Agreement, Magnitude, Upside, and Surprise.

Agreement is the extent to which all brokerage analysts are revising their earnings estimates in the same direction. The greater the percentage of analysts revising their estimates higher, the better chance the stock will outperform.

Magnitude is the size of the recent change in the consensus estimate for the current and next fiscal years.

Upside is the difference between the most accurate estimate, which is calculated by Zacks, and the consensus estimate.

Surprise is made up of a company's last few quarters' earnings per share surprises; companies with a positive earnings surprise are more likely to beat expectations in the future.

Each factor is given a raw score, which is recalculated every night and compiled into the Zacks Rank. Utilizing this data, stocks are put into five different groups: Strong Buy, Buy, Hold, Sell, and Strong Sell.

The Power of Institutional InvestorsThe Zacks Rank also allows individual investors, or retail investors, to benefit from the power of institutional investors.

Institutional investors are the professionals who manage the trillions of dollars invested in mutual funds, investment banks, and hedge funds. Studies have shown that these investors can and do move the market due to the large amounts of money they invest with. Because of this, the market tends to move in the same direction as institutional investors.

In order to figure out the fair value of a company and its shares, these investors will build valuation models focused on earnings and earnings expectations. Because if you raise estimates for the bottom line, it creates a higher fair value for a company.

With these changes, institutional investors will act, usually buying stocks with rising estimates and selling those with falling estimates. An increase in earnings expectations can potentially lead to higher stock prices and bigger gains for the investor.

Retail investors who get in at the first sign of upward revisions have a distinct advantage over larger investors since it can often take weeks, if not months, for an institutional investor to build a position. They'll also benefit from the expected institutional buying that could follow.

Not only can the Zacks Rank help you take advantage of trends in earnings estimate revisions, but it can also provide a way to get into stocks that are highly sought after by professionals.

How to Invest with the Zacks RankThe Zacks Rank is known for transforming investment portfolios. In fact, a portfolio of Zacks Rank #1 (Strong Buy) stocks has beaten the market in 26 of the last 32 years, with an average annual return of +23.94%.

Moreover, stocks with a new #1 (Strong Buy) ranking have some of the biggest profit potential, while those that fell to a #4 (Sell) or #5 (Strong Sell) have some of the worst.

Let's take a look at Carpenter Technology (CRS - Free Report) , which was added to the Zacks Rank #1 list on July 16, 2026. Philadelphia, PA-based Carpenter Technology Corporation is a producer and distributor of premium specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels as well as drilling tools. The company’s provides solutions for critical applications across diversified end-use markets - Aerospace and Defense (accounting for around 50.1% of the company’s revenues), Energy (5.3%), Transportation (3%), Medical (10.3%), Industrial and Consumer (12.3%) and Distribution (2.9%).

For fiscal 2026, four analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.09 to $10.58 per share. CRS boasts an average earnings surprise of 9%.

Earnings are expected to grow 41.4% for the current fiscal year, while revenue is projected to increase 8.5%.

CRS has been moving higher over the past four weeks as well, up 1.9% compared to the S&P 500's gain of 0.3%.

Bottom LineWith a #1 (Strong Buy) ranking, positive trend in earnings estimate revisions, and strong market momentum, Carpenter Technology should be on investors' shortlist.

If you want even more information on the Zacks Ranks, or one of our many other investing strategies, check out the Zacks Education home page.

Discover Today's Top StocksOur private Zacks #1 Rank List, based on our quantitative Zacks Rank stock-rating system, has more than doubled the S&P 500 since 1988. Applying the Zacks Rank in your own trading can boost your investing returns on your very next trade. See Today's Zacks #1 Rank List >>

Institutions push shares of Carpenter Technology Corporation (CRS) up 2,261% since 2005.

CRS produces and distributes specialty alloys, including titanium, powder metals, stainless steels, alloy steels, tool steels, and drilling tools, with defense and aerospace companies being major customers along with energy, transportation, medical, and industrial firms. Its third-quarter fiscal 2026 earnings report showed record quarterly adjusted operating income of $186.5 million (a 20% sequential gain), gross profit of $251.8 million (a 25% jump), and diluted per-share earnings of $2.77. The company reports again on July 30.

No wonder CRS shares are up 83% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock.

Carpenter Technology Attracting Institutional Capital Institutional volumes reveal plenty. In the last year, CRS has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in CRS shares. They reflect our proprietary inflow signal, pushing the stock higher:

CRS gained 107% in a year thanks to institutional inflows. Source: www.moneyflows.com Plenty of materials names are under accumulation right now. But there’s a powerful fundamental story happening with Carpenter Technology.

Carpenter Technology Fundamental Analysis Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, CRS has had strong sales and earnings growth:

3-year sales growth rate (+17.1%) 3-year EPS growth rate (+163.2%) Source: FactSet

Also, EPS is estimated to ramp higher this year by +22%.

Now it makes sense why the stock has been generating Big Money interest. CRS has a track record of strong financial performance.

Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.

Carpenter Technology has been a top-rated stock at MoneyFlows. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

CRS produced 15 rare Outlier 20 inflow signals in the last year. The blue bars below show when the stock was a top pick…Big Money loves this stock:

CRS has drawn 36 outlier inflow signals since 2005, with 15 coming in the last year. Source: www.moneyflows.com Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Carpenter Technology Price Prediction The CRS action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in CRS at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights.

The Basic Materials group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Carpenter Technology (CRS - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.

Carpenter Technology is a member of our Basic Materials group, which includes 275 different companies and currently sits at #13 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Carpenter Technology is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for CRS' full-year earnings has moved 3.3% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.

According to our latest data, CRS has moved about 83.8% on a year-to-date basis. Meanwhile, the Basic Materials sector has returned an average of 6.7% on a year-to-date basis. This means that Carpenter Technology is performing better than its sector in terms of year-to-date returns.

Element Solutions (ESI - Free Report) is another Basic Materials stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 59.3%.

For Element Solutions, the consensus EPS estimate for the current year has increased 1.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).

Looking more specifically, Carpenter Technology belongs to the Steel - Speciality industry, a group that includes 6 individual stocks and currently sits at #30 in the Zacks Industry Rank. This group has gained an average of 69.7% so far this year, so CRS is performing better in this area.

In contrast, Element Solutions falls under the Chemical - Specialty industry. Currently, this industry has 46 stocks and is ranked #93. Since the beginning of the year, the industry has moved +13.4%.

Carpenter Technology and Element Solutions could continue their solid performance, so investors interested in Basic Materials stocks should continue to pay close attention to these stocks.

After reaching an important support level, Carpenter Technology (CRS - Free Report) could be a good stock pick from a technical perspective. CRS surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

The 20-day simple moving average is a popular investing tool. Traders like this SMA because it offers a look back at a stock's price over a shorter period and helps smooth out price fluctuations. The 20-day can also show more trend reversal signals than longer-term moving averages.

Like other SMAs, if a stock's price is moving above the 20-day, the trend is considered positive. When the price falls below the moving average, it can signal a downward trend.

Shares of CRS have been moving higher over the past four weeks, up 5.1%. Plus, the company is currently a Zacks Rank #2 (Buy) stock, suggesting that CRS could be poised for a continued surge.

Looking at CRS's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 3 revisions higher for the current fiscal year compared to none lower, and the consensus estimate has moved up as well.

Investors should think about putting CRS on their watchlist given the ultra-important technical indicator and positive move in earnings estimate revisions.

Carpenter Technology (CRS - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.

The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.

Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.

Therefore, the Zacks rating upgrade for Carpenter basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

For Carpenter, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.

Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for CarpenterThis maker of stainless steels and special alloys is expected to earn $10.56 per share for the fiscal year ending June 2026, which represents no year-over-year change.

Analysts have been steadily raising their estimates for Carpenter. Over the past three months, the Zacks Consensus Estimate for the company has increased 3.1%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of Carpenter to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Carpenter Technology (CRS - Free Report) . This company, which is in the Zacks Steel - Speciality industry, shows potential for another earnings beat.

This maker of stainless steels and special alloys has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 6.43%.

For the most recent quarter, Carpenter was expected to post earnings of $2.59 per share, but it reported $2.77 per share instead, representing a surprise of 6.95%. For the previous quarter, the consensus estimate was $2.2 per share, while it actually produced $2.33 per share, a surprise of 5.91%.

Price and EPS Surprise

Thanks in part to this history, there has been a favorable change in earnings estimates for Carpenter lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Carpenter has an Earnings ESP of +0.09% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #2 (Buy), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on July 30, 2026.

With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss.

Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.

Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.

By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.

However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects.

Carpenter Technology (CRS - Free Report) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank.

Research shows that stocks carrying the best growth features consistently beat the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.

While there are numerous reasons why the stock of this maker of stainless steels and special alloys is a great growth pick right now, we have highlighted three of the most important factors below:

Earnings GrowthArguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. And for growth investors, double-digit earnings growth is definitely preferable, and often an indication of strong prospects (and stock price gains) for the company under consideration.

While the historical EPS growth rate for Carpenter is 138.7%, investors should actually focus on the projected growth. The company's EPS is expected to grow 41.2% this year, crushing the industry average, which calls for EPS growth of 39.9%.

Cash Flow GrowthCash is the lifeblood of any business, but higher-than-average cash flow growth is more beneficial and important for growth-oriented companies than for mature companies. That's because, high cash accumulation enables these companies to undertake new projects without raising expensive outside funds.

Right now, year-over-year cash flow growth for Carpenter is 33.8%, which is higher than many of its peers. In fact, the rate compares to the industry average of 13.1%.

While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 14.3% over the past 3-5 years versus the industry average of 12.5%.

Promising Earnings Estimate RevisionsSuperiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

There have been upward revisions in current-year earnings estimates for Carpenter. The Zacks Consensus Estimate for the current year has surged 0.2% over the past month.

Bottom LineCarpenter has not only earned a Growth Score of A based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

This combination positions Carpenter well for outperformance, so growth investors may want to bet on it.

Advancing financing partner alignment for BTC Structured Income Program; in active discussions on a pilot transaction with a major U.S. insurer for Credit Rating Securities Toronto, Ontario and New York, New York--(Newsfile Corp. - June 23, 2026) - DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF)  ("DelphX" or the "Company") today provided a corporate update on two of its principal commercialization workstreams. BTC Structured Income Program - Financing Partner Alignment The Company is pleased to report that it has finalized and executed a definitive agreement with a leading global digital asset lender - recognized as one of the most active and established credit providers in the cryptocurrency sector - for the senior secured lending facility that forms the foundational layer of capital for the Company's BTC Structured Income Program (the "Program").

Shares in Poolbeg Pharma PLC (AIM:POLB) rose 3% to 7.8p on Tuesday, taking their gain for the year to date to around 100%, after the drug developer secured a key European patent.

The European Patent Office has agreed to grant a patent covering POLB 001, Poolbeg's experimental treatment for preventing cytokine release syndrome (CRS), a dangerous immune reaction triggered by some cancer immunotherapies.

Cavendish, which rates the shares a buy with a 19p target, called it the most commercially significant milestone yet in Poolbeg's CRS patent family.

The grant extends protection across European Patent Office member states, one of the most valuable pharmaceutical regions, and follows recent awards in Australia and Canada.

The claims cover the use of p38 MAPK inhibitors, including POLB 001, to prevent CRS.

Cavendish said the broadening patent estate strengthens Poolbeg's hand in any partnering talks, with robust protection across major markets a prerequisite for pharmaceutical engagement.

That matters as larger drugmakers hunt for differentiated assets to offset looming patent expiries, the broker added.

The timing is notable, with Poolbeg's TOPICAL trial moving towards interim data this summer.

That study is testing POLB 001 as a preventative therapy in relapsed or refractory multiple myeloma patients treated with teclistamab, a bispecific antibody.

Site activation is complete and recruitment is underway, leaving the readout as a key near-term catalyst, according to Cavendish.

The broker sees a sizeable and growing market, as wider use of bispecific antibodies and CAR-T therapies pushes up the incidence of CRS.

Cavendish views POLB 001's mechanism as well aligned to that need, with payers and clinicians increasingly alert to the cost of CRS-related complications.

Genmab A/S (Nasdaq: GMAB) today announced new data from two studies evaluating epcoritamab, a T-cell engaging antibody administered subcutaneously, in the first-line (1L) treatment of patients with diffuse large B-cell lymphoma (DLBCL) who may have limited treatment options due to advanced age or multiple health conditions. Results from the Phase 2 EPCORE® DLBCL-3 study showed an overall response rate (ORR) of 67% and a complete response (CR) rate of 58% with epcoritamab monotherapy in elderly patients with newly diagnosed DLBCL. In the Phase 1b/2 EPCORE NHL-2 study, epcoritamab plus rituximab plus dose-attenuated cyclophosphamide, doxorubicin, vincristine, and prednisone (R-mini-CHOP) demonstrated an ORR of 93% and a CR rate of 86% in elderly patients with newly diagnosed DLBCL.

The results from both studies were presented in two poster presentations (abstracts PS2082 and PF1007) at the European Hematology Association (EHA) 2026 Congress held in Stockholm, Sweden, June 11-14. Additionally, the full EPCORE DLBCL-3 results have been simultaneously published in The Lancet Haematology.

EPCORE DLBCL-3 Results
The Phase 2 EPCORE DLBCL-3 study (abstract PS2082) evaluated the efficacy and safety of fixed-duration epcoritamab monotherapy in newly diagnosed CD20+ large B-cell lymphoma (LBCL) patients ineligible for anthracycline-based chemotherapy due to age (≥80 years) or comorbidities (≥75 years with comorbidities). Among 66 enrolled patients, the median age was 82.5 years, and all had comorbid conditions (94% with ≥3 comorbidities). With a median follow-up of 21.9 months, epcoritamab monotherapy demonstrated responses in this population with high unmet medical need.

An ORR of 67% and a CR rate of 58% were observed in evaluable patients (n=66). Median time to response was 1.5 months, and median time to CR was 2.2 months. Notably, 11 of 17 patients with a partial response or stable disease at first assessment subsequently achieved a CR.

"For newly diagnosed elderly patients with diffuse large B-cell lymphoma and comorbidities, who are often excluded from standard curative chemotherapy and ineligible for doxorubicin, finding more options is paramount," said Umberto Vitolo, M.D. Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Turin), Italy. "The EPCORE DLBCL-3 study showed that epcoritamab monotherapy offers robust data. Importantly, its safety profile, including cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, was consistent with expected rates in this fragile population with a high unmet medical need for new therapeutic options."

Responses were durable, with median duration of response (DOR) and duration of complete response (DOCR) not reached. At 12 months, an estimated 67% of responses and 73% of CRs remained ongoing. Median progression-free survival (PFS) was 13.0 months, while median overall survival (OS) was not reached; an estimated 43% of patients remained progression-free and 62% were alive at 18 months. High rates of minimal residual disease (MRD) negativity were observed, with 92% of evaluable responders achieving MRD negativity, typically by Cycle 3 Day 1 and sustained through Cycle 12 Day 1 in most patients.

The safety profile was consistent with expected rates in this elderly population. Cytokine release syndrome (CRS) occurred in 71% of patients, most commonly during Cycle 1, and immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 18%. Infections of any grade occurred in 68% of patients (26% Grade ≥3), and neutropenia was reported in 16%, with no febrile neutropenia or clinical tumor lysis syndrome observed. Eight Grade 5 TEAEs occurred.

EPCORE NHL-2, Arm 8 Results
Arm 8 of the Phase 1b/2 EPCORE NHL-2 study (abstract PF1007) evaluated epcoritamab plus R-mini-CHOP in 28 newly diagnosed CD20+ DLBCL patients ineligible for full-dose R-CHOP due to age (≥75 years) or comorbidities (≥65 years with comorbidities). With more than two years of follow-up, fixed-duration epcoritamab plus R-mini-CHOP demonstrated high response rates, sustained MRD negativity and durable remissions.

An ORR of 93% and a CR rate of 86% were observed. Median DOR, DOCR, PFS, and OS were not reached. At two years, estimated DOR and DOCR rates were 79%, while estimated PFS and OS rates were 76% and 82%, respectively.

“The EPCORE NHL-2 Arm 8 results are very encouraging, showing that combining epcoritamab with R-mini-CHOP led to high overall response rates and complete response rates, rapid and sustained minimal residual disease negativity, and durable remissions in this population,” said David Belada, M.D., Department of Internal Medicine—Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic. “These outcomes, alongside a consistent safety profile, potentially support the integration of epcoritamab with standard of care for these vulnerable patients, and highlight its broad utility in combinations across a range of disease settings and patient populations."

Rapid and sustained MRD negativity was observed, with 95% of evaluable patients achieving MRD negativity, including high rates in high-risk subgroups. Outcomes compared favorably with historical results for R-mini-CHOP alone.

The safety profile was consistent with prior reports and the known safety profiles of epcoritamab and R-mini-CHOP. The most common Grade ≥3 treatment-emergent adverse events (TEAEs) were neutropenia (54%), serious infections (33%) and anemia (14%). Most Grade ≥3 serious infections occurred during the first six cycles of treatment with R-mini-CHOP coadministration. TEAEs led to epcoritamab discontinuation in three patients (11%).

“Genmab is committed to evaluating epcoritamab as a potential treatment option in earlier lines of therapy for patients who traditionally struggle with aggressive treatment," said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. "The robust data observed in both the monotherapy and combination approaches reinforce our vision of making epcoritamab a foundational therapy across the spectrum of B-cell malignancies. These Phase 2 results support our ongoing commitment to addressing the significant unmet medical needs of elderly and comorbid patients, as we seek to identify effective, less intensive and tolerable options."

About Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) DLBCL is the most common type of non-Hodgkin lymphoma (NHL) worldwide, accounting for approximately 25-30 percent of all NHL cases.i,ii DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men.iii,iv DLBCL is a fast-growing type of NHL, a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. For many people living with DLBCL, their cancer either relapses, which means it may return after treatment, or becomes refractory, meaning it does not respond to treatment. Although new therapies have become available, treatment management can remain a challenge.iv,v

About the EPCORE® DLBCL-3 Trial
EPCORE DLBCL-3 (NCT05660967) is an open-label, randomized, global, Phase 2 trial to evaluate the efficacy and safety of epcoritamab as monotherapy or in combination with lenalidomide as first-line therapy for anthracycline-ineligible subjects with diffuse large B-cell lymphoma (DLBCL). This is a 2-stage trial. In Stage 1, eligible patients were randomized to either epcoritamab monotherapy or epcoritamab plus lenalidomide. In Stage 2, additional patients were enrolled to the epcoritamab monotherapy arm. Each treatment cycle is 28 days. Patients will receive a maximum of 12 cycles (up to 1 year) of treatment. The primary objective is to evaluate the clinical efficacy of epcoritamab monotherapy or epcoritamab and lenalidomide. The primary endpoint is to achieve a complete response rate determined by Lugano criteria. Additional secondary endpoints include overall response rate, duration of response, duration of complete response, rate of minimal residual disease negativity, progression-free survival and overall survival.

More information on this trial can be found at www.clinicaltrials.gov/.

About the EPCORE® NHL-2 Trial
EPCORE NHL-2 (NCT04663347) is a Phase 1b/2 open-label interventional trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab as a monotherapy and in combination with other standard of care agents in patients with B-cell non-Hodgkin lymphoma (B-NHL). The trial consists of two parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The primary objective of Part 1 is safety, and the primary goal of Part 2 is preliminary efficacy. The primary efficacy endpoint is overall response rate (ORR) based on best overall response per Lugano criteria. MRD negativity was assessed as a secondary endpoint.

More information on this trial can be found at www.clinicaltrials.gov.

About Epcoritamab
Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells.vi

Epcoritamab (approved under the brand name EPKINLY® in the U.S. and Japan, and TEPKINLY® in the EU) has received regulatory approval in certain lymphoma indications in more than 65 territories. Where approved, epcoritamab is a readily accessible therapy. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational relapsed or refractory (R/R) follicular lymphoma (FL) indication and additional approvals for the R/R diffuse large B-cell lymphoma (DLBCL) indication.

Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes several Phase 3, open-label, randomized trials, including a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL (NCT05578976), a trial evaluating epcoritamab in combination with lenalidomide compared to chemotherapy infusion in patients with R/R DLBCL (NCT06508658), and a trial evaluating epcoritamab in combination with lenalidomide and rituximab (R2) compared to chemoimmunotherapy in patients with previously untreated FL (NCT06191744). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit www.clinicaltrials.gov for more information.

What is EPKINLY?
EPKINLY is a prescription medicine used to treat adults with:

certain types of diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma that has come back (relapsed) or that did not respond (refractory) after 2 or more treatments. follicular lymphoma (FL) that has come back or that did not respond to previous treatment, together with lenalidomide and rituximab follicular lymphoma (FL) that has come back or that did not respond after 2 or more treatments. EPKINLY for the treatment of DLBCL is approved based on patient response data. Studies are ongoing to confirm the clinical benefit of EPKINLY.

It is not known if EPKINLY is safe and effective in children.

IMPORTANT SAFETY INFORMATION
Important Warnings—EPKINLY can cause serious side effects, including:

Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 or 3 smaller step-up doses of EPKINLY before your first full dose during your first cycle of treatment), and you may also receive other medicines before and for 3 days after receiving EPKINLY. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. Neurologic problems that can be serious, and can be life-threatening, and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY. People with DLBCL or high-grade B-cell lymphoma may be hospitalized after receiving their first full dose of EPKINLY on Day 15 of Cycle 1 due to the risk of CRS and neurologic problems.

People with FL may be hospitalized after receiving their first full dose of EPKINLY on Day 22 of Cycle 1 due to the risk of CRS and neurologic problems.

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. These may be symptoms of CRS or neurologic problems. If you have any symptoms that impair consciousness, do not drive or use heavy machinery or do other dangerous activities until your symptoms go away.

EPKINLY can cause other serious side effects, including:

Infections that may lead to death. Your healthcare provider will check you for signs and symptoms of infection before and during treatment and treat you as needed if you develop an infection. You should receive medicines from your healthcare provider before you start treatment to help prevent infection. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, feeling weak or generally unwell, or confusion. Low blood cell counts, which can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia and lymphopenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems. Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. If you are a female who can become pregnant, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

The most common side effects of EPKINLY when used alone in DLBCL or high-grade B-cell lymphoma or FL include CRS, injection site reactions, tiredness, muscle and bone pain, fever, diarrhea, COVID-19, rash, and stomach-area (abdominal) pain. The most common severe abnormal laboratory test results with EPKINLY when used alone include decreased white blood cells, decreased red blood cells, and decreased platelets.

The most common side effects of EPKINLY when used together with lenalidomide and rituximab in FL include rash, upper respiratory tract infections, tiredness, injection site reactions, constipation, diarrhea, CRS, pneumonia, COVID-19, and fever. The most common severe abnormal laboratory test results with EPKINLY when used together with lenalidomide and rituximab include decreased white blood cells and decreased platelets.

These are not all of the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see Medication Guide, including Important Warnings.

About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

This Media Release contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filingswith the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. EPCORE®, EPKINLY®, TEPKINLY® and their designs are trademarks of AbbVie Biotechnology Ltd.

____________________ i Lymphoma Research Foundation. Diffuse Large B-Cell Lymphoma. Accessed February 2026. https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/dlbcl/

ii Padala, et al. Diffuse Large B-Cell Lymphoma. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 Apr 24.

iii Sehn, et al. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384:842-858. doi: 10.1056/NEJMra2027612.

iv Kanas, et al. Epidemiology of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) in the United States and Western Europe: Population-Level Projections for 2020-2025. Leuk Lymphoma. 2022;63(1):54-63. doi: 10.1080/10428194.2021.1975188.

v Crump, et al. Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results From the International SCHOLAR-1 Study. Blood. 2017;130(16):1800-1808. doi: 10.1182/blood-2017-03-769620.

vi Engelberts PJ, Hiemstra IH, de Jong B, et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020;52:102625. DOI: 10.1016/j.ebiom.2019.102625.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610278575/en/

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Carpenter Technology (CRS - Free Report) , a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Carpenter Technology currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market? In order to see if CRS is a promising momentum pick, let's examine some Momentum Style elements to see if this maker of stainless steels and special alloys holds up.

A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.

For CRS, shares are up 0.45% over the past week while the Zacks Steel - Speciality industry is up 3.79% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 12.94% compares favorably with the industry's 12.94% performance as well.

Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Over the past quarter, shares of Carpenter Technology have risen 23.61%, and are up 114.39% in the last year. In comparison, the S&P 500 has only moved 7.09% and 29.83%, respectively.

Investors should also pay attention to CRS's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. CRS is currently averaging 717,576 shares for the last 20 days.

Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with CRS.

Over the past two months, 3 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost CRS's consensus estimate, increasing from $10.28 to $10.43 in the past 60 days. Looking at the next fiscal year, 3 estimates have moved upwards while there have been no downward revisions in the same time period.

Bottom LineTaking into account all of these elements, it should come as no surprise that CRS is a #2 (Buy) stock with a Momentum Score of A. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Carpenter Technology on your short list.

The Allspring SMID Cap Growth Fund underperformed the Russell 2500 Growth Index benchmark during the first quarter that ended March 31, 2026. Carpenter Technology is benefiting from increased production rates at Boeing and recent regulatory approvals that are driving demand for mission-critical materials and components. As one of only a few contractors capable of building large-scale power plants, Argan benefits from pricing power and strong demand across both gas-fired and renewable projects tied to grid modernization.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreWhat if you like to use all three types of investing? The VGM Score is a combination of all Style Scores, making it one of the most comprehensive indicators to use with the Zacks Rank. It rates each stock on their combined weighted styles, which helps narrow down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Carpenter Technology (CRS - Free Report) Philadelphia, PA-based Carpenter Technology Corporation is a producer and distributor of premium specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels as well as drilling tools. The company’s provides solutions for critical applications across diversified end-use markets - Aerospace and Defense (accounting for around 50.1% of the company’s revenues), Energy (5.3%), Transportation (3%), Medical (10.3%), Industrial and Consumer (12.3%) and Distribution (2.9%).

CRS is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

Additionally, the company could be a top pick for growth investors. CRS has a Growth Style Score of A, forecasting year-over-year earnings growth of 39.4% for the current fiscal year.

Three analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.15 to $10.43 per share. CRS boasts an average earnings surprise of +9%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, CRS should be on investors' short list.

On May 21, 2026, Carpenter Technology Corp (CRS) shares rose 3.9% today, bringing the current price to $438.32. The stock has seen a 52-week range between $219.